Please use this identifier to cite or link to this item: http://hdl.handle.net/10419/24058
Authors: 
Entorf, Horst
Fegert, Jörg
Kölch, Michael
Year of Publication: 
2004
Series/Report no.: 
ZEW Discussion Papers 04-49
Abstract: 
As the innovation process of pharmaceuticals is a long, risky and very costly business, economists typically emphasise lack of profit incentives and small market size as the most important obstacles to child-related innovative activity. Moreover, there are ethical concerns because children are not able to give their ?informed consent? to requested clinical trials. Thus, economic incentives, legal restrictions and ethical concerns seem to be responsible for the lack of innovative activity targeted at drugs for children, though social costbenefit considerations (i.e. welfare analysis) would most probably predict a high gain from the introduction of critical innovations. Grounded on a highly interdisciplinary view based on medical, pharmaceutical and economic research, this survey aims at analysing channels of influence that might be helpful both in the analysis of the innovation process of drugs for children, and in improving the uncertain situation of pediatric therapy.
Document Type: 
Working Paper

Files in This Item:
File
Size
427.68 kB





Items in EconStor are protected by copyright, with all rights reserved, unless otherwise indicated.